about
Approaches of targeting Rho GTPases in cancer drug discoverySignaling, Regulation, and Specificity of the Type II p21-activated KinasesSmall molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agents.Gfi1b controls integrin signaling-dependent cytoskeleton dynamics and organization in megakaryocytes.Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat.Anti-cancer effect of novel PAK1 inhibitor via induction of PUMA-mediated cell death and p21-mediated cell cycle arrest.Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety.The p21-activated kinase, PAK2, is important in the activation of numerous pancreatic acinar cell signaling cascades and in the onset of early pancreatitis eventsLiposome-mediated delivery of the p21 activated kinase-1 (PAK-1) inhibitor IPA-3 limits prostate tumor growth in vivo.Study on the expression of PAK4 and P54 protein in breast cancer.Protein kinase D1 (PKD1) phosphorylation on Ser203 by type I p21-activated kinase (PAK) regulates PKD1 localization.P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells.Targeting PAK1.Subverting Host Cell P21-Activated Kinase: A Case of Convergent Evolution across Pathogens.Prognostic significance of PAK4 expression in gastric cancer.Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor Series.A key role for Rac and Pak signaling in neutrophil extracellular traps (NETs) formation defines a new potential therapeutic target.PAK4 crystal structures suggest unusual kinase conformational movements.Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.Endothelial Cdc42 deficiency impairs endothelial regeneration and vascular repair after inflammatory vascular injury.Advances in the 1-phenanthryl-tetrahydroisoquinoline series of PAK4 inhibitors: potent agents restrain tumor cell growth and invasion.Melanoma-associated mutants within the serine-rich domain of PAK5 direct kinase activity to mitogenic pathways.PAK1 regulates ATXN1 levels providing an opportunity to modify its toxicity in Spinocerebellar ataxia type 1.Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL
P2860
Q26851300-3D1D7284-F5FF-411A-A530-C6150C908946Q28083745-F3D7E8DE-E9AD-46DA-B8C2-653C93CD4E4BQ28261026-EC029F13-C28D-4199-BFB4-49A8333D256FQ33438370-DA9C2F32-6F5C-4A1F-AE25-86D9D68FF031Q33604851-C700EB23-EA26-418D-9B73-6E6B3582A410Q33618830-33A8F406-4C9F-49F2-BBB6-D5AB484D019CQ34506833-64B4AC96-B08D-49BE-9178-5C07A090D34FQ36840241-E2934BF2-A881-478F-B303-8873A707E37AQ36957793-D0E2688E-8044-4BCB-9555-D6E1D55F8210Q37001333-2539EC49-AB0C-4D50-9C85-B31AB240C97AQ38707749-FB801FAD-A60D-460B-ABE0-2340A12AFBABQ38722990-8469488D-05AD-49B1-8DF9-23476A792DB7Q38757029-90E3FA78-FE81-4A13-97BC-F4AF40FD9BC8Q39254514-23E06657-FF0B-4612-94ED-F4F8347CEBD7Q41091136-E9C37D00-90EB-4884-9359-B159F1ABF8B2Q42430718-C8110F4A-6372-4E17-B2E4-E117791E8D3EQ46264202-17A1EEE5-EF24-48A3-B7CF-73CC8F6C569BQ47675076-F4B16463-0F57-4BC3-AC04-885DDA603932Q49165551-B327DFB1-29B6-4C98-B28C-049424DECE66Q49996639-0B13BFEC-709E-4BAB-828D-FC485B439988Q53061788-7EB31EE9-04DF-4518-9D15-362818BB8724Q54976847-130AAF54-9A7E-4F7C-8161-896AEE7F4E3DQ54977291-7CE357E6-699F-40D3-BD05-AD7569F74AF8Q57287566-66BEF091-CEF6-42BB-A346-CA0ABBC72BEA
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Inhibitors of p21-activated kinases (PAKs).
@en
type
label
Inhibitors of p21-activated kinases (PAKs).
@en
prefLabel
Inhibitors of p21-activated kinases (PAKs).
@en
P2093
P356
P1476
Inhibitors of p21-activated kinases (PAKs)
@en
P2093
Joachim Rudolph
Klaus P Hoeflich
Weiru Wang
P304
P356
10.1021/JM501613Q
P407
P577
2014-12-03T00:00:00Z